PT  - JOURNAL ARTICLE
AU  - Alnaggar, Mohammed
AU  - Xu, Yan
AU  - Li, Jingxia
AU  - He, Junyi
AU  - Chen, Jibing
AU  - Li, Man
AU  - Wu, Qingling
AU  - Lin, Li
AU  - Liang, Yingqing
AU  - Wang, Xiaohua
AU  - Li, Jiawei
AU  - Hu, Yi
AU  - Chen, Yan
AU  - Xu, Kecheng
AU  - Wu, Yangzhe
AU  - Yin, Zhinan
TI  - Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
AID  - 10.1186/s40425-019-0501-8
DP  - 2019 Dec 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - 36
VI  - 7
IP  - 1
4099  - http://jitc.bmj.com/content/7/1/36.short
4100  - http://jitc.bmj.com/content/7/1/36.full
SO  - J Immunother Cancer2019 Dec 01; 7
AB  - Background Cholangiocarcinoma (CCA) is a highly aggressive and fatal tumor. CCA occurs in the epithelial cells of bile ducts. Due to increasing incidences, CCA accounts for 3% of all gastrointestinal malignancies. In addition to comprehensive treatments for cancer, such as surgery, chemotherapy, and radiotherapy, during the past few years, cellular immunotherapy has played an increasingly important role. As a result of our research, we have discovered the γδ T cell-based immunotherapy for CCA.Case presentation A 30-year-old male (https://www.clinicaltrials.gov/ ID: NCT02425735) was diagnosed with recurrent mediastinal lymph node metastasis after liver transplantation because of Cholangiocarcinoma (stage IV). In the course of his therapy sessions, he only received allogenic γδ T cell immunotherapy from August, 2017 through February, 2018 (8 infusions in total). γδ T cells were expanded from peripheral blood mononuclear cells (PBMCs) of healthy donor, and ~ 4 × 108 cells were adoptive transferred to the patient.Conclusion In the above case report of the Cholangiocarcinoma (stage IV) patient who had received liver transplantation and afterward was diagnosed with recurrent mediastinal lymph node metastasis, we clinically proved that allogenic γδ T cell treatment had no adverse effects. We observed that allogenic γδ T cell treatments positively regulated peripheral immune functions of the patient, depleted tumor activity, improved quality of life, and prolonged his life span. After 8 γδ T cell treatments, the size of lymph nodes was remarkably reduced with activity depletion. This clinical work suggested that allogenic γδ T cell immunotherapy could be developed into a promising therapy drug for CCA.Kecheng Xu, Yangzhe Wu and Zhinan Yin contributed equally to this work.Mohammed Alnaggar and Yan Xu share the first authorship.Abbreviations:CCACholangiocarcinomaI 125Iodine-125PBMCsPeripheral blood mononuclear cellsPSCPrimary Sclerosing CholangitisγδGamma delta